Filgotinib
Jyseleca (filgotinib) is a small molecule pharmaceutical. Filgotinib was first approved as Jyseleca on 2020-09-24. It has been approved in Europe to treat rheumatoid arthritis. The pharmaceutical is active against tyrosine-protein kinase JAK1. In addition, it is known to target tyrosine-protein kinase JAK3, non-receptor tyrosine-protein kinase TYK2, and tyrosine-protein kinase JAK2.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
No data
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
No data
Clinical
Clinical Trials
60 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Arthritis | D001168 | HP_0001369 | M05-M14 | 3 | 9 | 7 | 5 | 4 | 28 |
| Rheumatoid arthritis | D001172 | EFO_0000685 | M06.9 | 2 | 7 | 5 | 6 | 4 | 24 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Ulcerative colitis | D003093 | EFO_0000729 | K51 | — | 1 | 4 | — | 4 | 8 |
| Colitis | D003092 | EFO_0003872 | K52.9 | — | 1 | 4 | — | 3 | 7 |
| Crohn disease | D003424 | EFO_0000384 | K50 | — | 3 | 2 | — | 1 | 6 |
| Ulcer | D014456 | MPATH_579 | — | — | 1 | 4 | — | 2 | 6 |
| Psoriatic arthritis | D015535 | EFO_0003778 | L40.5 | — | 3 | 2 | — | — | 5 |
| Spondylarthritis | D025241 | — | — | — | 2 | 3 | — | — | 5 |
| Spondylitis | D013166 | — | M46.9 | — | 2 | 3 | — | — | 5 |
| Ankylosing spondylitis | D013167 | EFO_0003898 | M45 | — | 2 | 2 | — | — | 4 |
| Inflammatory bowel diseases | D015212 | EFO_0003767 | — | — | 2 | 1 | — | 1 | 3 |
| Axial spondyloarthritis | D000089183 | — | — | — | 1 | 1 | — | — | 2 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Uveitis | D014605 | HP_0000554 | H20.9 | — | 1 | — | — | — | 1 |
| Non-radiographic axial spondyloarthritis | D000089202 | — | — | — | 1 | — | — | — | 1 |
| Kidney diseases | D007674 | EFO_0003086 | N08 | — | 1 | — | — | — | 1 |
| Membranous glomerulonephritis | D015433 | EFO_0004254 | N03.2 | — | 1 | — | — | — | 1 |
| Intestinal diseases | D007410 | HP_0002242 | K63.9 | — | 1 | — | — | — | 1 |
| Systemic lupus erythematosus | D008180 | HP_0002725 | M32 | — | 1 | — | — | — | 1 |
| Cutaneous lupus erythematosus | D008178 | EFO_0003834 | L93.1 | — | 1 | — | — | — | 1 |
| Sjogren's syndrome | D012859 | EFO_0000699 | M35.0 | — | 1 | — | — | — | 1 |
| Syndrome | D013577 | — | — | — | 1 | — | — | — | 1 |
| Myositis | D009220 | EFO_0000783 | G72.49 | — | 1 | — | — | — | 1 |
Show 2 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | — | — | 7 | — | — | — | — | 7 |
| Renal insufficiency | D051437 | HP_0000083 | N19 | 1 | — | — | — | — | 1 |
| Biological availability | D001682 | — | — | 1 | — | — | — | — | 1 |
| Juvenile arthritis | D001171 | EFO_1002007 | M08 | 1 | — | — | — | — | 1 |
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Filgotinib |
| INN | filgotinib |
| Description | Filgotinib, sold under the brand name Jyseleca, is a medication used for the treatment of rheumatoid arthritis (RA). It was developed by the Belgian-Dutch biotech company Galapagos NV.
|
| Classification | Small molecule |
| Drug class | tyrosine kinase inhibitors |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | O=C(Nc1nc2cccc(-c3ccc(CN4CCS(=O)(=O)CC4)cc3)n2n1)C1CC1 |
Identifiers
| PDB | — |
| CAS-ID | 1206161-97-8 |
| RxCUI | — |
| ChEMBL ID | CHEMBL3301607 |
| ChEBI ID | — |
| PubChem CID | 49831257 |
| DrugBank | DB14845 |
| UNII ID | 3XVL385Q0M (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
JAK3
JAK3
Variants
No data
Financial
Revenue by drug
$
€
£
â‚£
Jyseleca – Galapagos
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Estimated US medical usage
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 1,464 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
151 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use